Regístrese
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Involvement of the receptor for advanced glycation end products in liver transpl...
Journal Information
Vol. 14. Issue 2.
Pages 190-197 (March - April 2015)
Share
Share
Download PDF
More article options
Visits
48
Vol. 14. Issue 2.
Pages 190-197 (March - April 2015)
DOI: 10.1016/S1665-2681(19)30781-1
Open Access
Involvement of the receptor for advanced glycation end products in liver transplantation
Visits
48
Teresa Navarra*,***, Paolo De Simone**,***, Serena Del Turco*, Franco Filipponi**, Giuseppina Basta
,
Corresponding author
lapina@ifc.cnr.it

Correspondence and reprint request:
* Institute of Clinical Physiology, National Research Council, Pisa, Italy
** Hepatobiliary surgery and Liver Transplantation, University of Pisa Medical School Hospital, Pisa, Italy
*** Hepatobiliary surgery and Liver Transplantation, University of Pisa Medical School Hospital, Pisa, Italy
This item has received
48
Visits

Under a Creative Commons license
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (4)
Show moreShow less
Tables (2)
Table 1. Donor and recipient clinical and biochemical characteristics.
Table 2. Comparison between donors and recipients in hepatic full-length RAGE and esRAGE mRNA expression.
Show moreShow less
Abstract

Background and aim. Receptor for advanced glycation end products (RAGE) blockade by a soluble form of RAGE (sRAGE) appears to be protective against hepatocellular death and necrosis after I/R injury. Little is known about the role of the hepatic RAGE, its ligands, and the plasma levels of sRAGE in liver transplantation (LT).

Material and methods. This was a prospective study on patients (n = 28) undergoing deceased donor LT. RAGE ligands [the N(epsilon)-carboxy-methyl-lysine (CML) adduct and the high-mobility group box 1 (HMGB1) protein] and sRAGE levels were measured in donors at the time of organ procurement, while in recipients they were tested before surgery (baseline), after graft reperfusion, and on day 1 and 7 posttransplantation. Donors and recipients liver biopsies were collected to assess the transcriptional expression of the full-length RAGE and of its truncated isoform, the endogenous secreted RAGE (esRAGE).

Results. At baseline, CML levels were higher in LT recipients than in donors (p = 0.02), decreased immediately after graft reperfusion (p < 0.0001) and returned to baseline values on day 7. Baseline HMGB1 levels (3.8 ± 2.3 ng/mL) increased after graft reperfusion (39.9±18 ng/mL, p < 0.0001), and returned to baseline values within day 1, while circulating sRAGE decreased significantly on day 7 (p < 0.0001). The graft esRAGE mRNA expression was inversely associated with bilirubin on day 7 (β = -0.62, p = 0.005).

Conclusions. Early on after LT, there is accumulation of CML and a rapid increase of HMGB1 concurrent with a remarkable decline in circulating sRAGE. The RAGE-ligand axis may also be involved in early graft dysfunction.

Keywords:
High-mobility group box 1
N(epsilon)-carboxy-methyl-lysine
Liver transplantation
I/R injury
Full Text
Introduction

Early allograft dysfunction (EAD) may affect up to 25% of liver transplant (LT) recipients and entails a sevenfold and a tenfold higher risk for graft loss and patient death, respectively.1 Both during surgery and in the post-operative period, the liver graft may be injured by several toxic factors, such as hypotension, hypoxia, ischemia/reperfusion (I/R) injury, and use of hepatotoxic drugs. Although the mechanisms leading to EAD have not yet been entirely elucidated, its development is believed to be largely due to I/R injury, which is associated with cell death, oxidative damage and a severe inflammatory response within the liver.24 In turn, the extent of I/R injury may be related to the cold ischemia time, graft quality, donor age, the recipient’s clinical status at transplantation, and surgical challenges. From a bio-molecular perspective, liver graft injury and EAD may result in altered expression of serum proteins associated with an inflammatory response.5 Recently, several chemokines and cytokines –such as the monocyte chemotactic protein-1, interleukin-8, RANTES, interferon-γ inducible protein 10 and the interleukin-2 receptor- appear to increase in the early post-operative period of EAD recipients.6

There is experimental evidence that interaction between the receptor for advanced glycation end products (RAGE) and its ligands plays a pivotal role in liver inflammation and tissue regeneration after liver injury.7,8 RAGE interacts with pro-inflammatory ligands, such as the carboxy-methyllysine ad-ducts (CML), the high-mobility group box 1 (HMGB1) protein and the S100/calgranulins among others, thus resulting in amplification of inflammation and tissue injury.9,11 On the other hand, RAGE blockade by a soluble form of RAGE significantly increases animal survival after extended liver resection and appears to be protective against hepatocellular death and necrosis after I/R injury.7,8,12 RAGE is detectable in blood as a soluble isoform that consists of the extracellular ligandbinding domain only. The total circulating isoforms of soluble RAGE (sRAGE) include endogenous secreted isoforms (esRAGE) generated via alternative splicing, and a truncated form generated through proteolytic cleavage of the full-length cell-surface receptor.13 Both isoforms can bind RAGE ligands and contribute to their removal by competing with the membrane-bound RAGE, thus resulting in a cytoprotective effect.14,15

Over the last decade, clinical studies performed on patients undergoing lung, kidney, or LT have documented the involvement of the RAGE-ligand axis in the post-transplantation inflammation and regeneration processes.1619 Cirrhotic patients undergoing LT show high levels of plasma CML before surgery which decrease by 50% at 3 months post-transplantation, thus confirming that the liver acts as a clearing organ for these adducts.18 The circulating and pro-inflammatory RAGE ligand HMGB1 -which is present in the cell nucleus and can be released by necrotic cells or in response to hypoxia−20,21 peaks in blood after graft reperfusion concurrent with hepatic HMGB1 expression up-regulation.19

The interaction between RAGE and its ligands can thus impair liver regeneration, while sRAGE can have a protective role. Hence, we set up a prospective trial to evaluate the plasma levels of circulating RAGE ligands and/or sRAGE peri-operatively and in the early post-operative period, concurrent with assessment of the hepatic sRAGE/RAGE transcriptional expression in both graft recipients and their donors.

Material and MethodsPatient selection

This was a 12-month, prospective, single-centre study on the behaviour of the RAGE-ligand axis in 28 patients submitted to primary, whole-size, deceased donor LT performed at our institution from November 2010 to April 2012. The current report focuses on the first 7 day post-transplantation.

Patients were enrolled if adults (≥ 18 years) and affected with clinically documented chronic liver disease of viral, metabolic, autoimmune, toxic and/or innate aetiology with or without hepatocellular carcinoma (HCC), and if they provided informed consent. Exclusion criteria called for: acute liver failure; a model for end-stage liver disease (MELD) score ≥ 30 at transplantation; HCC beyond Milan criteria as per the pre-transplant clinical investigations; non-HCC liver neoplasms (i.e. cholangiocarcinoma, adenomatosis, hemangioendothelioma); acute and/or chronic kidney disease (defined as serum creatinine ≥ 1.5 mg/dL at transplantation); a body mass index (BMI) > 27 kg/m2; combined organ transplantation; abstinence from alcohol use < 6 months; autoimmune liver disease on active steroid treatment; hepatitis C virus (HCV)-related disease on treatment with interferon at the time of transplantation; history of major cardiovascular event, such as acute myocardial infarction, unstable angina, previous coronary revascularization, stroke and peripheral vascular disease grade ≥ 2; hepato-pulmonary syndrome with arterial hypoxemia (PaO2) < 70 mmHg or an alveolar-arterial gradient > 20 mmHg; porto-pulmonary hypertension with a mean pulmonary arterial pressure > 25 mmHg; and mental impairment. At the time of transplantation, patients were re-screened for compliance with the eligibility criteria and underwent laboratory tests. The MELD score at transplantation was derived as indicated elsewhere.22 Patients were re-evaluated for shortterm complications for 7 days following LT by collecting clinical data, and routine blood parameters. Patients did not develop any complications within this observation period.

Approval was obtained from the institutional review board. The study was carried out in compliance with the principles set forth in the 2008 Seoul revision of the declaration of Helsinki.

Liver biopsies

Two biopsies were obtained from the donor liver graft during procurement and from the recipient’s liver explant, respectively, and were stored at −20°C in RNAlater (Sigma-Aldrich, St. Louis, MO, USA) for tissue stabilization.

Blood sample collection

Blood samples were obtained preoperatively from donors and recipients. In the recipient, further samples were collected within 30 min after graft reperfusion, on days 1 and 7. Blood samples were centrifuged at 4 °C and plasma was immediately stored at −80 °C until analysis. All laboratory tests were performed in blinded fashion with respect to the identity of the samples. Routine biochemical analyses were determined by standard laboratory methods.

Determination of plasma sRAGE levels

Plasma sRAGE levels were determined using a double-sandwich ELISA kit (DuoSet ELISA development kit; R&D Systems, Minneapolis, MN, USA) as previously described.23 Intra-assay and inter-assay coefficients of variation was 5.9% and 8.2%, respectively. The lower limit of detection of sRAGE was 21.5 pg/mL.

Determination of plasma CML levels

Plasma CML levels were measured by an inhouse competitive ELISA using the mouse F(ab’)2 fragment anti-AGE monoclonal antibody (clone 6D12) (ICN Biochemical Division, Aurora, OH,USA), as previously described.24 The lower limit of detection of CML was 0.5 μg/mL.

Determination of plasma HMGB1 levels

Plasma HMGB1 levels were determined using the double-sandwich ELISA Kit II (IBL International, Hamburg, Germany) according to the manufacturers’ description. Intra-assay and inter-assay coefficients of variation were <8% and 10% respectively. Plasma samples from 30 healthy voluntaries were assayed as control (49.3 ± 12.3 years). The sensitivity of the assay was 0.1 ng/mL.

RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR)

Total RNA was extracted from liver specimens by using the RNeasy Midi kit (Qiagen S.p.A, Milan, Italy) as previously described.25 The RNA concentration was determined spectrophotometrically at 260 nm (BioPhotometer Eppendorf Italia, Milan, Italy). Integrity and purity of total RNA were checked by electrophoresis of samples on ethidium bromide 2% agarose gel and visualized at 302 nm (2UVTM Transilluminator, UVP, Upland, CA, USA).

Total RNA was reverse-transcribed using the iS-cript cDNA synthesis kit (Bio-Rad Laboratories, Inc,Hercules, CA, USA). The cDNA was amplified using the Taq PCR Core Kit (Qiagen, Germany) with specific primers and conditions as shown below, in a GeneAmp PCR System 9700 thermal cycler (Perkin Elmer/Applied Biosystems, Foster City, CA, USA).

All PCR reactions were performed in a 50 µL total volume, containing Taq polimerase (Qiagen, Germany) 2.5 U, deoxyribonucleotide triphosphate (dNTP) 0.2 mmol/L, MgCl2 1.5 mmol/L and 1 µmol/ L of both forward and reverse primers. The Primers, annealing temperature and cycles used were respectively:

  • For RAGE gene, F: 5’-CAGGAATGGAAAGGAGACCA-3’, R: 5’-CCCTTCTCATTAGGCACCAG3’, 62°C (30 sec.) and 40 cycles.

  • For esRAGE gene, F: 5’-GGGGATGGTCAACAAGAAAGG-3’, R: 5’- AGGTTCCTCCGACTGATTCAGTTC -3’, 55°C (15 sec) and 40 cycles.

  • For GAPDH gene, F: 5’-GGTCTCCTCTGACTTCAACAGCG-3’, R: 5’-GGTACTTTATTGATGGTACATGAC-3’, 55° (1 min) and 30 cycles.

The amplified products were electrophoresed on ethidium bromide 2% agarose gel, in parallel with a DNA Ladder 100 bp (Qiagen, Germany). After gel image acquisition by a digital camera (Kodak DC290 Digital camera System; Eastman Kodak, Rochester, NY, USA), the band intensity of PCR DNA was quantified using densitometric analysis by Scion image™. PCR products of esRAGE and full-length RAGE were normalized to transcript levels of the control gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

Statistical analysis

The sample size was calculated with the Stata software (version 9.2; Stata Corp. College Station, TX, USA) by the estimated power for two-sample comparison of means of CML plasma values. A sample size of 56 patients (28 donors and 28 recipients) would provide 85% power to detect differences of 30% in CML value between two groups with a two-sided Student t-test at an αlevel of 0.05.

Data were analysed with the use of statistical software SPSS 13.0 (SPSS Inc, Chicago, IL, USA). The Kolmogorov-Smirnov test of normality was used to verify whether the distribution of variables followed a Gaussian pattern. According to the level of distribution, data are presented as mean ± standard deviations (SD), medians and interquartile ranges. Variables with a non-normal distribution were logarithmically transformed before each analysis. The unpaired Student’s t-test was used to compare normally distributed variables between donors and recipients. Multiple differences were evaluated by one-way ANOVA followed by the Bonferroni’s post-hoc test. Simple correlations were evaluated by linear regression analysis. A two-tailed p-value < 0.05 was considered statistically significant.

Results

Donor age, cold and warm ischemia, recipient clinical and biochemical characteristics, and post-transplant markers of liver injury are illustrated in table 1. Recipients were mainly males (82%), and the most frequent indication for LT was HCC (64%). Mean recipients’ age was lower than their donors’ (53 ± 8.7 vs. 62.1 ± 17.3 years, respectively; p = 0.017).

Table 1.

Donor and recipient clinical and biochemical characteristics.

• Donors (N = 28)     
Age (years)  62.1 ± 17.3   
• Recipients (N = 28)     
Age (years)  53 ± 8.7*   
Male (%)  23 (82)   
Primary diagnosis, n (%)     
HCC  7 (25)   
HCC + HCV + cirrhosis  7 (25)   
HCC + HBV + cirrhosis  2 (7.1)   
HCV + cirrhosis  5 (17.9)   
HCC + HBV  1 (3.6)   
HCC + HCV  1 (3.6)   
Caroli’s syndrome  2 (7.1)   
Primary sclerosing cholangitis  2 (7.1)   
Alcoholic cirrhosis  1 (3.6)   
Ascites, n (%)  10 (36)   
MELD score  9.48 ± 3.79   
Graft cold ischemia time (min)  451.4 ± 91   
Graft warm ischemia time (min)  87 ± 15   
  Prior LT  On day 7 
ALT (U/L)  69 (42-90.5)  89 (76.2-119.8)  
AST (U/L)  72.5 (59-134.5)  40 (31.2-56.8) 
GGT (U/L)  141.5 (104-197.5)  159 (106-220) 
LDH (U/L)  232.7 ± 59.1  234.8 ± 39.4 
Bilirubin (mg/dL)  1.51 (1.1-2.5)  3.28 (1.8-4.4)§ 
INR  1.27 ± 0.19  1.17 ± 0.13 
Creatinine (mg/dL)  0.826 ± 0.202  0.937 ± 0.495 
Antithrombin III (%)  50 (38-73)   
Cholinesterase (U/L)  2663 (2,049-5,335)   

Data are presented as mean ± SD, median and interquartile range or percentage. HCC: hepato-cellular carcinoma. ALT: alanine aminotransferase. AST: aspartate aminotransferase. GGT: gamma-glutamyl transpeptidase. LDH: lactate dehydrogenase. MELD: model for end-stage liver disease.

*

p = 0.017 vs. donors’ age.

p < 0.05 vs. prior LT.

p < 0.0001 vs. prior LT.

§

p = 0.0008 vs. prior LT.

At baseline, among the RAGE-ligands CML plasma levels were higher in LT recipients than donors (p = 0.02) (Figure 1A) and decreased immediately after graft reperfusion (p < 0.0001) to return to baseline values on day 1 (Figure 1A). The baseline HMGB1 levels did not differ between LT recipients and donors (3.8 ± 2.3 ng/mL vs. 3.3 ± 2.4 ng/mL, respectively) (Figure 1B). However, in both groups they were significantly (p < 0.0001) higher than in a group (30 subjects) of normal controls (0.45 ± 0.3 ng/mL). The baseline HMGB1 levels in LT recipients correlated with the preoperative MELD score (ß = 0.45, p < 0.05) (Figure 2). The baseline HMGB1 levels increased dramatically after graft reperfusion (39.9 ± 18 ng/mL, p < 0.0001) returning rapidly to baseline values one day after LT (3.6 ± 2.9 ng/mL) (Figure 1B). The peak values of HMGB1 after reperfusion tended to correlate directly with the MELD score on day 7 (β = 0.42, p = 0.07).

Figure 1.

Comparison between donors and recipients (n = 28) prior to LT in plasma levels of CML (A), HMGB1 (B) and sRAGE (C) and kinetics of the same parameters in LT recipients at 7 days after LT. Data are presented as mean ± SD. Comparison between donors and LT recipients was evaluated by t-test while kinetics in LT recipient was evaluated by ANOVA followed by Bonferroni test.

(0.03MB).
Figure 2.

Simple direct correlation between baseline HMGB1 and the MELD score of the patients (n = 28) prior LT.

(0.01MB).

The preoperative plasma levels of sRAGE did not differ between LT recipients and donors (Figure 1C). Plasma sRAGE levels did not change early after LT, but decreased significantly on day 7 (p < 0.0001) (Figure 1C). The decrease of sRAGE levels observed in the current patients’ population is illustrated in figure 3.

Figure 3.

The sRAGE plasma levels are shown for each patient prior LT and 7 days after surgery. Median (95% CI) is shown. The P < 0.0001 value was evaluated by t-test on the logarithmically transformed data.

(0.01MB).

Semi-quantitative RT-PCR analysis revealed that hepatic full-length RAGE mRNA expression differed between donors and LT recipients (p = 0.005) while esRAGE mRNA did not differ between two groups (Table 2). The graft esRAGE mRNA expression was significantly and inversely associated with bilirubin levels on day 7 (β = - 0.62, p = 0.005) (Figure 4).

Table 2.

Comparison between donors and recipients in hepatic full-length RAGE and esRAGE mRNA expression.

  Donors (n = 28)  Recipients (n = 28)  P value 
Tissue RAGE (%)  46.4 ±11.4  56.6 ± 10.0  0.005 
Tissue esRAGE (%)  19.7 ± 13.9  16 ± 12.6  n.s. 

Data are presented as mean ± SD.

Figure 4.

Simple inverse correlation between graft esRAGE mRNA expression and bilirubin levels on day 7.

(0.02MB).
Discussion

This study provides evidence supporting the involvement of RAGE and RAGE-ligands in the cascade of biological events following liver graft procurement and transplantation.

We found that, after transplantation, the circulating levels of sRAGE -which are the result of its expression in tissues and release into the bloodstream- decrease by day 7. Since sRAGE might exert inhibitory effects on RAGE, acting as a decoy, but also binding to cell surface RAGE to block the formation of homodimers,26 decreased levels of sRAGE may contribute to enhanced RAGE-mediated pro-inflammatory signalling after transplantation and I/R injury. These changes in circulating sRAGE levels after LT may not only be due to decreased expression/release -and possibly affected by immunosuppression-27 but also to enhanced clearance. However, in the current series baseline, serum creatinine did not change significantly vs. day 7, and the first hypothesis seems much more plausible and warrants further investigation. In agreement with our observation, previous research in kidney transplantation has demonstrated that circulating sRAGE levels decline after surgery and this is associated with a two- to threefold higher risk for mortality in kidney recipients.17

Among RAGE ligands, the most remarkable indicator of liver impairment is the HMGB1 protein, which is present into the cell nucleus and can be released by cells undergoing necrosis or in response to hypoxia.20,21 In agreement with Ilmakunnas, et al.,19 our data confirm that HMGB1 plasma levels increase early on after reperfusion, probably as a result of I/R injury and tended to correlate to MELD score on day 7. That is compatible with the hypothesis that, following ischemia-reperfusion, the early release of HMGB1 activates the RAGE and as a result of this interaction the effects of the injury are amplified and revealed later.

Furthermore, we also found higher values of HMGB1 in LT recipients than in normal subjects, and a positive relationship between baseline HMGB1 protein and pre-operative MELD score. These results underline the role of this marker in chronic liver disease and suggest that HMGB1 may in turn have a harmful impact on graft function. The LT recipients had higher hepatic expression of RAGE than donors. Nevertheless, we do not have a plausible explanation for this and we believe that other investigations are need to know the reason of this difference. We also found higher CML levels in LT recipients than in donors, possibly as consequence of reduced AGE clearance due to liver impairment. However, after a rapid drop ensuing graft reperfusion, CML levels returned to pre-transplant values on day 7, underscoring a poorly clarified reduced detoxification capacity of the liver graft early on after transplantation. An interesting relationship was the inverse association between esRAGE liver expression in donor grafts and recipients’ serum bilirubin on day 7 post-transplantation because low levels of the protective esRAGE could negatively influence the transplant in early follow-up, although the assessment of esRAGE in post-transplant biopsy (unfeasible for ethical concerns) would be of greater utility. Considering all of these results as a whole -i.e. the association between graft esRAGE and bilirubin levels on day 7, the rapid increase of HMGB1 after graft reperfusion, and the CML accumulation in the bloodstream followed by a dramatic decline of the protective sRAGE in the early postoperative period- we believe that these biological markers point out to metabolic events with the potential to affect graft survival and patient outcomes. The RAGE-ligand axis is a promising target of further investigation, as a biological marker of liver injury prior to and after LT. Identification of patients at risk of complications is crucial for improving post-operative care and transplant outcomes. The RAGE-ligand axis may also be used as a therapeutic target in order to enhance early graft function and improve survival.

Our study has several inherent limitations. This work is exploratory in nature and is a descriptive study, and therefore we cannot assign causality to our findings, nor can we recommend specific clinical strategies based on our conclusions. The sample size is the major limiting factor, and a prospective, larger validation set is needed for conclusions that are more robust. Despite these limitations, this study provides evidence for several associations between the cascade of biological events ensuing graft procurement, I/R, and reperfusion and the RAGEligands axis, and this can guide future investigation.

Abbreviations

  • CML: N(epsilon)-Carboxy-Methyl-Lysine.

  • EAD: early allograft dysfunction.

  • esRAGE: endogenous secreted RAGE.

  • HCC: hepatocellular carcinoma.

  • HMGB1: high-mobility group box 1.

  • I/R: ischemia/reperfusion.

  • LT: liver transplantation.

  • MELD: Model for End-Stage Liver Disease.

  • RAGE: receptor for advanced glycation end products.

  • sRAGE: soluble RAGE.

Funding Sources

This work was funded by institutional sources.

Conflict of Interest

The authors have no conflicts of interest to disclose.

Acknowledgments

The authors wish to thank Alison Frank for her editorial assistance and owe a deep debt of gratitude to the nurse staff of the Hepatobiliary surgery and liver transplant Unit, University of Pisa Medical School Hospital, Pisa, Italy.

References
[1.]
Olthoff K.M., Kulik L., Samstein B., Kaminski M., Abecassis M., Emond J., Shaked A., et al.
Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors.
Liver Transpl, 16 (2010), pp. 943-949
[2.]
Busuttil R.W., Tanaka K..
The utility of marginal donors in liver transplantation.
Liver Transpl, 9 (2003), pp. 651-663
[3.]
Totsukali E., Fung J.J., Ishizawa Y., Nishimura A., Ono H., Toyoki Y., Narumi S., et al.
Synergistic effect of cold and warm ischemia time on postoperative graft outcome in human liver transplantation.
Hepatogastroenterology, 51 (2004), pp. 1413-1416
[4.]
Briceno J., Ciria R..
Early graft dysfunction after liver transplantation.
Transplant Proc, 42 (2010), pp. 631-633
[5.]
Hassan L., Bueno P., Ferron-Celma I., Ramia J.M., Garrote D., Muffak K., Barrera L., et al.
Early postoperative response of cytokines in liver transplant recipients.
Transplant Proc, 38 (2006), pp. 2488-2491
[6.]
Friedman B.H., Wolf J.H., Wang L., Putt M.E., Shaked A., Christie J.D., Hancock W.W., et al.
Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation.
Liver Transpl, 18 (2012), pp. 166-176
[7.]
Cataldegirmen G., Zeng S., Feirt N., Ippagunta N., Dun H., Qu W., Lu Y., et al.
RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB.
J Exp Med, 201 (2005), pp. 473-484
[8.]
Zeng S., Feirt N., Goldstein M., Guarrera J., Ippagunta N., Ekong U., Dun H., et al.
Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice.
Hepatology, 39 (2004), pp. 422-432
[9.]
Del Turco S., Basta G..
An update on advanced glycation endproducts and atherosclerosis.
Biofactors, 38 (2012), pp. 266-274
[10.]
Hofmann M.A., Drury S., Fu C., Qu W., Taguchi A., Lu Y., Avila C., et al.
RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides.
Cell, 97 (1999), pp. 889-901
[11.]
Kislinger T., Fu C., Huber B., Qu W., Taguchi A., Du Yan S., Hofmann M., et al.
N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression.
J Biol Chem, 274 (1999), pp. 31740-31749
[12.]
Basta G., Navarra T., De Simone P., Del Turco S., Gastaldelli A., Filipponi F..
What is the role of the receptor for advanced glycation end products-ligand axis in liver injury?.
Liver Transpl, 17 (2011), pp. 633-640
[13.]
Raucci A., Cugusi S., Antonelli A., Barabino S.M., Monti L., Bierhaus A., Reiss K., et al.
A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10).
Faseb J, 22 (2008), pp. 3716-3727
[14.]
Yonekura H., Yamamoto Y., Sakurai S., Petrova R.G., Abedin M.J., Li H., Yasui K., et al.
Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury.
Biochem J, 370 (2003), pp. 1097-1109
[15.]
Schlueter C., Hauke S., Flohr A.M., Rogalla P., Bullerdiek J..
Tissue-specific expression patterns of the RAGE receptor and its soluble forms—a result of regulated alternative splicing?.
Biochim Biophys Acta, 1630 (2003), pp. 1-6
[16.]
Christie J.D., Shah C.V., Kawut S.M., Mangalmurti N., Lederer D.J., Sonett J.R., Ahya V.N., et al.
Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction.
Am J Respir Crit Care Med, 180 (2009), pp. 1010-1015
[17.]
Gross S., van Ree R.M., Oterdoom L.H., de Vries A.P., van Son W.J., de Jong P.E., Navis G.J., et al.
Low levels of sRAGE are associated with increased risk for mortality in renal transplant recipients.
Transplantation, 84 (2007), pp. 659-663
[18.]
Sebekova K., Kupcova V., Schinzel R., Heidland A..
Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - amelioration by liver transplantation.
J Hepatol, 36 (2002), pp. 66-71
[19.]
Ilmakunnas M., Tukiainen E.M., Rouhiainen A., Rauvala H., Arola J., Nordin A., Makisalo H., et al.
High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation.
Liver Transpl, 14 (2008), pp. 1517-1525
[20.]
Xia J.R., Liu N.F., Zhu N.X..
Specific siRNA Targeting the Receptor for Advanced Glycation End Products Inhibits Experimental Hepatic Fibrosis in Rats.
Int J Mol Sci, 9 (2008), pp. 638-661
[21.]
Lohwasser C., Neureiter D., Popov Y., Bauer M., Schuppan D..
Role of the receptor for advanced glycation end products in hepatic fibrosis.
World J Gastroenterol, 15 (2009), pp. 5789-5798
[22.]
Wiesner R.H., McDiarmid S.V., Kamath P.S., Edwards E.B., Malinchoc M., Kremers W.K., Krom R.A., et al.
MELD and PELD: application of survival models to liver allocation.
Liver Transpl, 7 (2001), pp. 567-580
[23.]
Basta G., Sironi A.M., Lazzerini G., Del Turco S., Buzzigoli E., Casolaro A., Natali A., et al.
Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.
J Clin Endocrinol Metab, 91 (2006), pp. 4628-4634
[24.]
Kaloudi O., Basta G., Perfetto F., Bartoli F., Del Rosso A., Miniati I., Conforti M.L., et al.
Circulating levels of Nepsilon(carboxymethyl)lysine are increased in systemic sclerosis.
Rheumatology (Oxford), 46 (2007), pp. 412-416
[25.]
Nannipieri M., Cecchetti F., Anselmino M., Mancini E., Marchetti G., Bonotti A., Baldi S., et al.
Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis.
Obes Surg, 19 (2009), pp. 467-474
[26.]
Zong H., Madden A., Ward M., Mooney M.H., Elliott C.T., Stitt A.W..
Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction.
J Biol Chem, 285 (2010), pp. 23137-23146
[27.]
Mu L., Zhang Y., Sun B., Wang J., Xie X., Li N., Zhang J., et al.
Activation of the receptor for advanced glycation end products (RAGE) exacerbates experimental autoimmune myasthenia gravis symptoms.
Clin Immunol, 141 (2012), pp. 36-48
Copyright © 2015. Fundación Clínica Médica Sur, A.C.
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.